Hereditary breast cancer - Revision history

Michael at 15:14, 9 June 2024

2024-06-09T15:14:52Z

← Older revision		Revision as of 15:14, 9 June 2024
Line 74:		Line 74:
	===Management===		===Management===
	*Women get prophylatic bilateral salpingo-oophorectomies and mastectomies.		*Women get prophylatic bilateral salpingo-oophorectomies and mastectomies.
	**The pathology yield in bilateral salpingo-oophorectomies is significant but modest; in series of 26 prophylatic surgeries (BRCA1 22 individuals, BRCA2 4 individuals) there were 2 in situ carcinoma and 2 atypical proliferations.<ref name=pmid14668548>{{Cite journal \| last1 = Carcangiu \| first1 = ML. \| last2 = Radice \| first2 = P. \| last3 = Manoukian \| first3 = S. \| last4 = Spatti \| first4 = G. \| last5 = Gobbo \| first5 = M. \| last6 = Pensotti \| first6 = V. \| last7 = Crucianelli \| first7 = R. \| last8 = Pasini \| first8 = B. \| title = Atypical epithelial proliferation in fallopian tubes in prophylactic salpingo-oophorectomy specimens from BRCA1 and BRCA2 germline mutation carriers. \| journal = Int J Gynecol Pathol \| volume = 23 \| issue = 1 \| pages = 35-40 \| month = Jan \| year = 2004 \| doi = 10.1097/01.pgp.0000101082.35393.84 \| PMID = 14668548 }}</ref> All of the pathology was in BRCA1 carriers.		**The pathology yield in [[Prophylactic bilateral salpingo-oophorectomy\|bilateral salpingo-oophorectomies]] is significant but modest; in series of 26 prophylatic surgeries (BRCA1 22 individuals, BRCA2 4 individuals) there were 2 in situ carcinoma and 2 atypical proliferations.<ref name=pmid14668548>{{Cite journal \| last1 = Carcangiu \| first1 = ML. \| last2 = Radice \| first2 = P. \| last3 = Manoukian \| first3 = S. \| last4 = Spatti \| first4 = G. \| last5 = Gobbo \| first5 = M. \| last6 = Pensotti \| first6 = V. \| last7 = Crucianelli \| first7 = R. \| last8 = Pasini \| first8 = B. \| title = Atypical epithelial proliferation in fallopian tubes in prophylactic salpingo-oophorectomy specimens from BRCA1 and BRCA2 germline mutation carriers. \| journal = Int J Gynecol Pathol \| volume = 23 \| issue = 1 \| pages = 35-40 \| month = Jan \| year = 2004 \| doi = 10.1097/01.pgp.0000101082.35393.84 \| PMID = 14668548 }}</ref> All of the pathology was in BRCA1 carriers.
	**In prophylatic procedures, the ovaries and tubes, endometrium, and lower uterine segment should all be [[submitted in total]].<ref name=pmid24495259>{{Cite journal \| last1 = Downes \| first1 = MR. \| last2 = Allo \| first2 = G. \| last3 = McCluggage \| first3 = WG. \| last4 = Sy \| first4 = K. \| last5 = Ferguson \| first5 = SE. \| last6 = Aronson \| first6 = M. \| last7 = Pollett \| first7 = A. \| last8 = Gallinger \| first8 = S. \| last9 = Bilbily \| first9 = E. \| title = Review of findings in prophylactic gynaecological specimens in Lynch syndrome with literature review and recommendations for grossing. \| journal = Histopathology \| volume = 65 \| issue = 2 \| pages = 228-39 \| month = Aug \| year = 2014 \| doi = 10.1111/his.12386 \| PMID = 24495259 }}</ref>		**In prophylatic procedures, the ovaries and tubes, endometrium, and lower uterine segment should all be [[submitted in total]].<ref name=pmid24495259>{{Cite journal \| last1 = Downes \| first1 = MR. \| last2 = Allo \| first2 = G. \| last3 = McCluggage \| first3 = WG. \| last4 = Sy \| first4 = K. \| last5 = Ferguson \| first5 = SE. \| last6 = Aronson \| first6 = M. \| last7 = Pollett \| first7 = A. \| last8 = Gallinger \| first8 = S. \| last9 = Bilbily \| first9 = E. \| title = Review of findings in prophylactic gynaecological specimens in Lynch syndrome with literature review and recommendations for grossing. \| journal = Histopathology \| volume = 65 \| issue = 2 \| pages = 228-39 \| month = Aug \| year = 2014 \| doi = 10.1111/his.12386 \| PMID = 24495259 }}</ref>
	*Poly(ADP-ribose) polymerases (PARP) inhibitors, e.g. olaparib.<ref name=pmid28250726>{{cite journal \|authors=Dziadkowiec KN, Gąsiorowska E, Nowak-Markwitz E, Jankowska A \|title=PARP inhibitors: review of mechanisms of action and BRCA1/2 mutation targeting \|journal=Prz Menopauzalny \|volume=15 \|issue=4 \|pages=215–219 \|date=December 2016 \|pmid=28250726 \|pmc=5327624 \|doi=10.5114/pm.2016.65667 \|url=}}</ref>		*Poly(ADP-ribose) polymerases (PARP) inhibitors, e.g. olaparib.<ref name=pmid28250726>{{cite journal \|authors=Dziadkowiec KN, Gąsiorowska E, Nowak-Markwitz E, Jankowska A \|title=PARP inhibitors: review of mechanisms of action and BRCA1/2 mutation targeting \|journal=Prz Menopauzalny \|volume=15 \|issue=4 \|pages=215–219 \|date=December 2016 \|pmid=28250726 \|pmc=5327624 \|doi=10.5114/pm.2016.65667 \|url=}}</ref>
Line 93:		Line 93:
	*[[Intraductal carcinoma of the prostate]] - associated with BRCA2.		*[[Intraductal carcinoma of the prostate]] - associated with BRCA2.
	*[[Ancillary testing in prostate cancer]].		*[[Ancillary testing in prostate cancer]].
			*[[Prophylactic bilateral salpingo-oophorectomy]].

	==References==		==References==

Michael: +RAD51

2024-02-13T16:02:38Z

+RAD51

← Older revision		Revision as of 16:02, 13 February 2024
Line 82:		Line 82:
	:See ''[[Uterus#BRCA_carrier]]''.		:See ''[[Uterus#BRCA_carrier]]''.

	==Other ~~mutations~~==		==Other genes==
	*BARD1 ~~mutations~~.<ref>{{cite journal \|author=Ratajska M, Antoszewska E, Piskorz A, ''et al.'' \|title=Cancer predisposing BARD1 mutations in breast-ovarian cancer families \|journal=Breast Cancer Res. Treat. \|volume=131 \|issue=1 \|pages=89–97 \|year=2012 \|month=January \|pmid=21344236 \|doi=10.1007/s10549-011-1403-8 \|url=}}</ref>		*BARD1 - associated with breast and ovarian cancer.<ref>{{cite journal \|author=Ratajska M, Antoszewska E, Piskorz A, ''et al.'' \|title=Cancer predisposing BARD1 mutations in breast-ovarian cancer families \|journal=Breast Cancer Res. Treat. \|volume=131 \|issue=1 \|pages=89–97 \|year=2012 \|month=January \|pmid=21344236 \|doi=10.1007/s10549-011-1403-8 \|url=}}</ref>
			*RAD51 - associated with breast and ovarian cancer.<ref>{{cite journal \|authors=Bonilla B, Hengel SR, Grundy MK, Bernstein KA \|title=RAD51 Gene Family Structure and Function \|journal=Annu Rev Genet \|volume=54 \|issue= \|pages=25–46 \|date=November 2020 \|pmid=32663049 \|pmc=7703940 \|doi=10.1146/annurev-genet-021920-092410 \|url=}}</ref>

	==See also==		==See also==
	*[[Breast cancer]].		*[[Breast cancer]].

Michael: /* See also */

2022-11-01T15:10:46Z

Michael: /* Management */

2022-01-13T18:23:50Z

Management

← Older revision		Revision as of 18:23, 13 January 2022
Line 76:		Line 76:
	**The pathology yield in bilateral salpingo-oophorectomies is significant but modest; in series of 26 prophylatic surgeries (BRCA1 22 individuals, BRCA2 4 individuals) there were 2 in situ carcinoma and 2 atypical proliferations.<ref name=pmid14668548>{{Cite journal \| last1 = Carcangiu \| first1 = ML. \| last2 = Radice \| first2 = P. \| last3 = Manoukian \| first3 = S. \| last4 = Spatti \| first4 = G. \| last5 = Gobbo \| first5 = M. \| last6 = Pensotti \| first6 = V. \| last7 = Crucianelli \| first7 = R. \| last8 = Pasini \| first8 = B. \| title = Atypical epithelial proliferation in fallopian tubes in prophylactic salpingo-oophorectomy specimens from BRCA1 and BRCA2 germline mutation carriers. \| journal = Int J Gynecol Pathol \| volume = 23 \| issue = 1 \| pages = 35-40 \| month = Jan \| year = 2004 \| doi = 10.1097/01.pgp.0000101082.35393.84 \| PMID = 14668548 }}</ref> All of the pathology was in BRCA1 carriers.		**The pathology yield in bilateral salpingo-oophorectomies is significant but modest; in series of 26 prophylatic surgeries (BRCA1 22 individuals, BRCA2 4 individuals) there were 2 in situ carcinoma and 2 atypical proliferations.<ref name=pmid14668548>{{Cite journal \| last1 = Carcangiu \| first1 = ML. \| last2 = Radice \| first2 = P. \| last3 = Manoukian \| first3 = S. \| last4 = Spatti \| first4 = G. \| last5 = Gobbo \| first5 = M. \| last6 = Pensotti \| first6 = V. \| last7 = Crucianelli \| first7 = R. \| last8 = Pasini \| first8 = B. \| title = Atypical epithelial proliferation in fallopian tubes in prophylactic salpingo-oophorectomy specimens from BRCA1 and BRCA2 germline mutation carriers. \| journal = Int J Gynecol Pathol \| volume = 23 \| issue = 1 \| pages = 35-40 \| month = Jan \| year = 2004 \| doi = 10.1097/01.pgp.0000101082.35393.84 \| PMID = 14668548 }}</ref> All of the pathology was in BRCA1 carriers.
	**In prophylatic procedures, the ovaries and tubes, endometrium, and lower uterine segment should all be [[submitted in total]].<ref name=pmid24495259>{{Cite journal \| last1 = Downes \| first1 = MR. \| last2 = Allo \| first2 = G. \| last3 = McCluggage \| first3 = WG. \| last4 = Sy \| first4 = K. \| last5 = Ferguson \| first5 = SE. \| last6 = Aronson \| first6 = M. \| last7 = Pollett \| first7 = A. \| last8 = Gallinger \| first8 = S. \| last9 = Bilbily \| first9 = E. \| title = Review of findings in prophylactic gynaecological specimens in Lynch syndrome with literature review and recommendations for grossing. \| journal = Histopathology \| volume = 65 \| issue = 2 \| pages = 228-39 \| month = Aug \| year = 2014 \| doi = 10.1111/his.12386 \| PMID = 24495259 }}</ref>		**In prophylatic procedures, the ovaries and tubes, endometrium, and lower uterine segment should all be [[submitted in total]].<ref name=pmid24495259>{{Cite journal \| last1 = Downes \| first1 = MR. \| last2 = Allo \| first2 = G. \| last3 = McCluggage \| first3 = WG. \| last4 = Sy \| first4 = K. \| last5 = Ferguson \| first5 = SE. \| last6 = Aronson \| first6 = M. \| last7 = Pollett \| first7 = A. \| last8 = Gallinger \| first8 = S. \| last9 = Bilbily \| first9 = E. \| title = Review of findings in prophylactic gynaecological specimens in Lynch syndrome with literature review and recommendations for grossing. \| journal = Histopathology \| volume = 65 \| issue = 2 \| pages = 228-39 \| month = Aug \| year = 2014 \| doi = 10.1111/his.12386 \| PMID = 24495259 }}</ref>
	*PARP inhibitors, e.g. olaparib.<ref name=pmid28250726>{{cite journal \|authors=Dziadkowiec KN, Gąsiorowska E, Nowak-Markwitz E, Jankowska A \|title=PARP inhibitors: review of mechanisms of action and BRCA1/2 mutation targeting \|journal=Prz Menopauzalny \|volume=15 \|issue=4 \|pages=215–219 \|date=December 2016 \|pmid=28250726 \|pmc=5327624 \|doi=10.5114/pm.2016.65667 \|url=}}</ref>		*Poly(ADP-ribose) polymerases (PARP) inhibitors, e.g. olaparib.<ref name=pmid28250726>{{cite journal \|authors=Dziadkowiec KN, Gąsiorowska E, Nowak-Markwitz E, Jankowska A \|title=PARP inhibitors: review of mechanisms of action and BRCA1/2 mutation targeting \|journal=Prz Menopauzalny \|volume=15 \|issue=4 \|pages=215–219 \|date=December 2016 \|pmid=28250726 \|pmc=5327624 \|doi=10.5114/pm.2016.65667 \|url=}}</ref>
	**Used in both germline and somatic BRCA-mutated cancers.		**Used in both germline and somatic BRCA-mutated cancers.

Michael: /* Management */

2022-01-13T18:22:49Z

Management

← Older revision		Revision as of 18:22, 13 January 2022
Line 76:		Line 76:
	**The pathology yield in bilateral salpingo-oophorectomies is significant but modest; in series of 26 prophylatic surgeries (BRCA1 22 individuals, BRCA2 4 individuals) there were 2 in situ carcinoma and 2 atypical proliferations.<ref name=pmid14668548>{{Cite journal \| last1 = Carcangiu \| first1 = ML. \| last2 = Radice \| first2 = P. \| last3 = Manoukian \| first3 = S. \| last4 = Spatti \| first4 = G. \| last5 = Gobbo \| first5 = M. \| last6 = Pensotti \| first6 = V. \| last7 = Crucianelli \| first7 = R. \| last8 = Pasini \| first8 = B. \| title = Atypical epithelial proliferation in fallopian tubes in prophylactic salpingo-oophorectomy specimens from BRCA1 and BRCA2 germline mutation carriers. \| journal = Int J Gynecol Pathol \| volume = 23 \| issue = 1 \| pages = 35-40 \| month = Jan \| year = 2004 \| doi = 10.1097/01.pgp.0000101082.35393.84 \| PMID = 14668548 }}</ref> All of the pathology was in BRCA1 carriers.		**The pathology yield in bilateral salpingo-oophorectomies is significant but modest; in series of 26 prophylatic surgeries (BRCA1 22 individuals, BRCA2 4 individuals) there were 2 in situ carcinoma and 2 atypical proliferations.<ref name=pmid14668548>{{Cite journal \| last1 = Carcangiu \| first1 = ML. \| last2 = Radice \| first2 = P. \| last3 = Manoukian \| first3 = S. \| last4 = Spatti \| first4 = G. \| last5 = Gobbo \| first5 = M. \| last6 = Pensotti \| first6 = V. \| last7 = Crucianelli \| first7 = R. \| last8 = Pasini \| first8 = B. \| title = Atypical epithelial proliferation in fallopian tubes in prophylactic salpingo-oophorectomy specimens from BRCA1 and BRCA2 germline mutation carriers. \| journal = Int J Gynecol Pathol \| volume = 23 \| issue = 1 \| pages = 35-40 \| month = Jan \| year = 2004 \| doi = 10.1097/01.pgp.0000101082.35393.84 \| PMID = 14668548 }}</ref> All of the pathology was in BRCA1 carriers.
	**In prophylatic procedures, the ovaries and tubes, endometrium, and lower uterine segment should all be [[submitted in total]].<ref name=pmid24495259>{{Cite journal \| last1 = Downes \| first1 = MR. \| last2 = Allo \| first2 = G. \| last3 = McCluggage \| first3 = WG. \| last4 = Sy \| first4 = K. \| last5 = Ferguson \| first5 = SE. \| last6 = Aronson \| first6 = M. \| last7 = Pollett \| first7 = A. \| last8 = Gallinger \| first8 = S. \| last9 = Bilbily \| first9 = E. \| title = Review of findings in prophylactic gynaecological specimens in Lynch syndrome with literature review and recommendations for grossing. \| journal = Histopathology \| volume = 65 \| issue = 2 \| pages = 228-39 \| month = Aug \| year = 2014 \| doi = 10.1111/his.12386 \| PMID = 24495259 }}</ref>		**In prophylatic procedures, the ovaries and tubes, endometrium, and lower uterine segment should all be [[submitted in total]].<ref name=pmid24495259>{{Cite journal \| last1 = Downes \| first1 = MR. \| last2 = Allo \| first2 = G. \| last3 = McCluggage \| first3 = WG. \| last4 = Sy \| first4 = K. \| last5 = Ferguson \| first5 = SE. \| last6 = Aronson \| first6 = M. \| last7 = Pollett \| first7 = A. \| last8 = Gallinger \| first8 = S. \| last9 = Bilbily \| first9 = E. \| title = Review of findings in prophylactic gynaecological specimens in Lynch syndrome with literature review and recommendations for grossing. \| journal = Histopathology \| volume = 65 \| issue = 2 \| pages = 228-39 \| month = Aug \| year = 2014 \| doi = 10.1111/his.12386 \| PMID = 24495259 }}</ref>
	*PARP inhibitors.<ref name=pmid28250726>{{cite journal \|authors=Dziadkowiec KN, Gąsiorowska E, Nowak-Markwitz E, Jankowska A \|title=PARP inhibitors: review of mechanisms of action and BRCA1/2 mutation targeting \|journal=Prz Menopauzalny \|volume=15 \|issue=4 \|pages=215–219 \|date=December 2016 \|pmid=28250726 \|pmc=5327624 \|doi=10.5114/pm.2016.65667 \|url=}}</ref>		*PARP inhibitors, e.g. olaparib.<ref name=pmid28250726>{{cite journal \|authors=Dziadkowiec KN, Gąsiorowska E, Nowak-Markwitz E, Jankowska A \|title=PARP inhibitors: review of mechanisms of action and BRCA1/2 mutation targeting \|journal=Prz Menopauzalny \|volume=15 \|issue=4 \|pages=215–219 \|date=December 2016 \|pmid=28250726 \|pmc=5327624 \|doi=10.5114/pm.2016.65667 \|url=}}</ref>
			**Used in both germline and somatic BRCA-mutated cancers.

	===Sign out===		===Sign out===

Michael: /* Management */

2022-01-13T18:21:05Z

Management

← Older revision		Revision as of 18:21, 13 January 2022
Line 76:		Line 76:
	**The pathology yield in bilateral salpingo-oophorectomies is significant but modest; in series of 26 prophylatic surgeries (BRCA1 22 individuals, BRCA2 4 individuals) there were 2 in situ carcinoma and 2 atypical proliferations.<ref name=pmid14668548>{{Cite journal \| last1 = Carcangiu \| first1 = ML. \| last2 = Radice \| first2 = P. \| last3 = Manoukian \| first3 = S. \| last4 = Spatti \| first4 = G. \| last5 = Gobbo \| first5 = M. \| last6 = Pensotti \| first6 = V. \| last7 = Crucianelli \| first7 = R. \| last8 = Pasini \| first8 = B. \| title = Atypical epithelial proliferation in fallopian tubes in prophylactic salpingo-oophorectomy specimens from BRCA1 and BRCA2 germline mutation carriers. \| journal = Int J Gynecol Pathol \| volume = 23 \| issue = 1 \| pages = 35-40 \| month = Jan \| year = 2004 \| doi = 10.1097/01.pgp.0000101082.35393.84 \| PMID = 14668548 }}</ref> All of the pathology was in BRCA1 carriers.		**The pathology yield in bilateral salpingo-oophorectomies is significant but modest; in series of 26 prophylatic surgeries (BRCA1 22 individuals, BRCA2 4 individuals) there were 2 in situ carcinoma and 2 atypical proliferations.<ref name=pmid14668548>{{Cite journal \| last1 = Carcangiu \| first1 = ML. \| last2 = Radice \| first2 = P. \| last3 = Manoukian \| first3 = S. \| last4 = Spatti \| first4 = G. \| last5 = Gobbo \| first5 = M. \| last6 = Pensotti \| first6 = V. \| last7 = Crucianelli \| first7 = R. \| last8 = Pasini \| first8 = B. \| title = Atypical epithelial proliferation in fallopian tubes in prophylactic salpingo-oophorectomy specimens from BRCA1 and BRCA2 germline mutation carriers. \| journal = Int J Gynecol Pathol \| volume = 23 \| issue = 1 \| pages = 35-40 \| month = Jan \| year = 2004 \| doi = 10.1097/01.pgp.0000101082.35393.84 \| PMID = 14668548 }}</ref> All of the pathology was in BRCA1 carriers.
	**In prophylatic procedures, the ovaries and tubes, endometrium, and lower uterine segment should all be [[submitted in total]].<ref name=pmid24495259>{{Cite journal \| last1 = Downes \| first1 = MR. \| last2 = Allo \| first2 = G. \| last3 = McCluggage \| first3 = WG. \| last4 = Sy \| first4 = K. \| last5 = Ferguson \| first5 = SE. \| last6 = Aronson \| first6 = M. \| last7 = Pollett \| first7 = A. \| last8 = Gallinger \| first8 = S. \| last9 = Bilbily \| first9 = E. \| title = Review of findings in prophylactic gynaecological specimens in Lynch syndrome with literature review and recommendations for grossing. \| journal = Histopathology \| volume = 65 \| issue = 2 \| pages = 228-39 \| month = Aug \| year = 2014 \| doi = 10.1111/his.12386 \| PMID = 24495259 }}</ref>		**In prophylatic procedures, the ovaries and tubes, endometrium, and lower uterine segment should all be [[submitted in total]].<ref name=pmid24495259>{{Cite journal \| last1 = Downes \| first1 = MR. \| last2 = Allo \| first2 = G. \| last3 = McCluggage \| first3 = WG. \| last4 = Sy \| first4 = K. \| last5 = Ferguson \| first5 = SE. \| last6 = Aronson \| first6 = M. \| last7 = Pollett \| first7 = A. \| last8 = Gallinger \| first8 = S. \| last9 = Bilbily \| first9 = E. \| title = Review of findings in prophylactic gynaecological specimens in Lynch syndrome with literature review and recommendations for grossing. \| journal = Histopathology \| volume = 65 \| issue = 2 \| pages = 228-39 \| month = Aug \| year = 2014 \| doi = 10.1111/his.12386 \| PMID = 24495259 }}</ref>
			*PARP inhibitors.<ref name=pmid28250726>{{cite journal \|authors=Dziadkowiec KN, Gąsiorowska E, Nowak-Markwitz E, Jankowska A \|title=PARP inhibitors: review of mechanisms of action and BRCA1/2 mutation targeting \|journal=Prz Menopauzalny \|volume=15 \|issue=4 \|pages=215–219 \|date=December 2016 \|pmid=28250726 \|pmc=5327624 \|doi=10.5114/pm.2016.65667 \|url=}}</ref>

	===Sign out===		===Sign out===

Michael: /* See also */

2021-04-26T18:28:38Z

Sarah A: /* See also */

2020-03-05T14:39:17Z

Michael: /* Management */

2018-06-06T19:33:44Z

Management

← Older revision		Revision as of 19:33, 6 June 2018
Line 75:		Line 75:
	*Women get prophylatic bilateral salpingo-oophorectomies and mastectomies.		*Women get prophylatic bilateral salpingo-oophorectomies and mastectomies.
	**The pathology yield in bilateral salpingo-oophorectomies is significant but modest; in series of 26 prophylatic surgeries (BRCA1 22 individuals, BRCA2 4 individuals) there were 2 in situ carcinoma and 2 atypical proliferations.<ref name=pmid14668548>{{Cite journal \| last1 = Carcangiu \| first1 = ML. \| last2 = Radice \| first2 = P. \| last3 = Manoukian \| first3 = S. \| last4 = Spatti \| first4 = G. \| last5 = Gobbo \| first5 = M. \| last6 = Pensotti \| first6 = V. \| last7 = Crucianelli \| first7 = R. \| last8 = Pasini \| first8 = B. \| title = Atypical epithelial proliferation in fallopian tubes in prophylactic salpingo-oophorectomy specimens from BRCA1 and BRCA2 germline mutation carriers. \| journal = Int J Gynecol Pathol \| volume = 23 \| issue = 1 \| pages = 35-40 \| month = Jan \| year = 2004 \| doi = 10.1097/01.pgp.0000101082.35393.84 \| PMID = 14668548 }}</ref> All of the pathology was in BRCA1 carriers.		**The pathology yield in bilateral salpingo-oophorectomies is significant but modest; in series of 26 prophylatic surgeries (BRCA1 22 individuals, BRCA2 4 individuals) there were 2 in situ carcinoma and 2 atypical proliferations.<ref name=pmid14668548>{{Cite journal \| last1 = Carcangiu \| first1 = ML. \| last2 = Radice \| first2 = P. \| last3 = Manoukian \| first3 = S. \| last4 = Spatti \| first4 = G. \| last5 = Gobbo \| first5 = M. \| last6 = Pensotti \| first6 = V. \| last7 = Crucianelli \| first7 = R. \| last8 = Pasini \| first8 = B. \| title = Atypical epithelial proliferation in fallopian tubes in prophylactic salpingo-oophorectomy specimens from BRCA1 and BRCA2 germline mutation carriers. \| journal = Int J Gynecol Pathol \| volume = 23 \| issue = 1 \| pages = 35-40 \| month = Jan \| year = 2004 \| doi = 10.1097/01.pgp.0000101082.35393.84 \| PMID = 14668548 }}</ref> All of the pathology was in BRCA1 carriers.
	**In prophylatic procedures, the ovaries and tubes, endometrium, and lower uterine segment should be [[submitted in total]].<ref name=pmid24495259>{{Cite journal \| last1 = Downes \| first1 = MR. \| last2 = Allo \| first2 = G. \| last3 = McCluggage \| first3 = WG. \| last4 = Sy \| first4 = K. \| last5 = Ferguson \| first5 = SE. \| last6 = Aronson \| first6 = M. \| last7 = Pollett \| first7 = A. \| last8 = Gallinger \| first8 = S. \| last9 = Bilbily \| first9 = E. \| title = Review of findings in prophylactic gynaecological specimens in Lynch syndrome with literature review and recommendations for grossing. \| journal = Histopathology \| volume = 65 \| issue = 2 \| pages = 228-39 \| month = Aug \| year = 2014 \| doi = 10.1111/his.12386 \| PMID = 24495259 }}</ref>		**In prophylatic procedures, the ovaries and tubes, endometrium, and lower uterine segment should all be [[submitted in total]].<ref name=pmid24495259>{{Cite journal \| last1 = Downes \| first1 = MR. \| last2 = Allo \| first2 = G. \| last3 = McCluggage \| first3 = WG. \| last4 = Sy \| first4 = K. \| last5 = Ferguson \| first5 = SE. \| last6 = Aronson \| first6 = M. \| last7 = Pollett \| first7 = A. \| last8 = Gallinger \| first8 = S. \| last9 = Bilbily \| first9 = E. \| title = Review of findings in prophylactic gynaecological specimens in Lynch syndrome with literature review and recommendations for grossing. \| journal = Histopathology \| volume = 65 \| issue = 2 \| pages = 228-39 \| month = Aug \| year = 2014 \| doi = 10.1111/his.12386 \| PMID = 24495259 }}</ref>

	===Sign out===		===Sign out===

Michael: /* Management */

2018-06-06T19:31:42Z

Management

← Older revision		Revision as of 19:31, 6 June 2018
Line 75:		Line 75:
	*Women get prophylatic bilateral salpingo-oophorectomies and mastectomies.		*Women get prophylatic bilateral salpingo-oophorectomies and mastectomies.
	**The pathology yield in bilateral salpingo-oophorectomies is significant but modest; in series of 26 prophylatic surgeries (BRCA1 22 individuals, BRCA2 4 individuals) there were 2 in situ carcinoma and 2 atypical proliferations.<ref name=pmid14668548>{{Cite journal \| last1 = Carcangiu \| first1 = ML. \| last2 = Radice \| first2 = P. \| last3 = Manoukian \| first3 = S. \| last4 = Spatti \| first4 = G. \| last5 = Gobbo \| first5 = M. \| last6 = Pensotti \| first6 = V. \| last7 = Crucianelli \| first7 = R. \| last8 = Pasini \| first8 = B. \| title = Atypical epithelial proliferation in fallopian tubes in prophylactic salpingo-oophorectomy specimens from BRCA1 and BRCA2 germline mutation carriers. \| journal = Int J Gynecol Pathol \| volume = 23 \| issue = 1 \| pages = 35-40 \| month = Jan \| year = 2004 \| doi = 10.1097/01.pgp.0000101082.35393.84 \| PMID = 14668548 }}</ref> All of the pathology was in BRCA1 carriers.		**The pathology yield in bilateral salpingo-oophorectomies is significant but modest; in series of 26 prophylatic surgeries (BRCA1 22 individuals, BRCA2 4 individuals) there were 2 in situ carcinoma and 2 atypical proliferations.<ref name=pmid14668548>{{Cite journal \| last1 = Carcangiu \| first1 = ML. \| last2 = Radice \| first2 = P. \| last3 = Manoukian \| first3 = S. \| last4 = Spatti \| first4 = G. \| last5 = Gobbo \| first5 = M. \| last6 = Pensotti \| first6 = V. \| last7 = Crucianelli \| first7 = R. \| last8 = Pasini \| first8 = B. \| title = Atypical epithelial proliferation in fallopian tubes in prophylactic salpingo-oophorectomy specimens from BRCA1 and BRCA2 germline mutation carriers. \| journal = Int J Gynecol Pathol \| volume = 23 \| issue = 1 \| pages = 35-40 \| month = Jan \| year = 2004 \| doi = 10.1097/01.pgp.0000101082.35393.84 \| PMID = 14668548 }}</ref> All of the pathology was in BRCA1 carriers.
			**In prophylatic procedures, the ovaries and tubes, endometrium, and lower uterine segment should be [[submitted in total]].<ref name=pmid24495259>{{Cite journal \| last1 = Downes \| first1 = MR. \| last2 = Allo \| first2 = G. \| last3 = McCluggage \| first3 = WG. \| last4 = Sy \| first4 = K. \| last5 = Ferguson \| first5 = SE. \| last6 = Aronson \| first6 = M. \| last7 = Pollett \| first7 = A. \| last8 = Gallinger \| first8 = S. \| last9 = Bilbily \| first9 = E. \| title = Review of findings in prophylactic gynaecological specimens in Lynch syndrome with literature review and recommendations for grossing. \| journal = Histopathology \| volume = 65 \| issue = 2 \| pages = 228-39 \| month = Aug \| year = 2014 \| doi = 10.1111/his.12386 \| PMID = 24495259 }}</ref>

	===Sign out===		===Sign out===

← Older revision		Revision as of 18:28, 26 April 2021
Line 86:		Line 86:
	*[[Hereditary diffuse gastric cancer]].		*[[Hereditary diffuse gastric cancer]].
	*[[Serous tubal intraepithelial carcinoma]].		*[[Serous tubal intraepithelial carcinoma]].
	*[[BRIP1]]		*[[BRIP1]].
			*[[Intraductal carcinoma of the prostate]] - associated with BRCA2.

	==References==		==References==

← Older revision		Revision as of 14:39, 5 March 2020
Line 86:		Line 86:
	*[[Hereditary diffuse gastric cancer]].		*[[Hereditary diffuse gastric cancer]].
	*[[Serous tubal intraepithelial carcinoma]].		*[[Serous tubal intraepithelial carcinoma]].
			*[[BRIP1]]

	==References==		==References==

← Older revision		Revision as of 15:10, 1 November 2022
Line 90:		Line 90:
	*[[BRIP1]].		*[[BRIP1]].
	*[[Intraductal carcinoma of the prostate]] - associated with BRCA2.		*[[Intraductal carcinoma of the prostate]] - associated with BRCA2.
			*[[Ancillary testing in prostate cancer]].

	==References==		==References==